Romiplostim

FDA approved

Romiplostim (Nplate) is a thrombopoietin receptor agonist approved by the FDA in 2008 for immune thrombocytopenia (ITP), a condition with dangerously low platelets.

At a glance

Where it acts: Heart & blood
Regulatory status: FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Romiplostim is a 'peptibody': peptides that activate the thrombopoietin receptor fused to an antibody fragment that extends its half-life. Activating the receptor stimulates bone marrow megakaryocytes to make more platelets.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

Joint and muscle pain, headache, dizziness, insomnia and abdominal pain.

Increased bone marrow fibers (reticulin), blood clots if platelets rise too high, and rebound low platelets after stopping.

Who Uses Romiplostim

Adults and children with chronic ITP who have not responded well to other treatments; also approved for radiation-induced bone marrow injury.